We used estrogen receptor positive breast CCLs, MCF7 and T47D, because tamoxifen has most often been used as the treatment for estrogen receptor positive breast cancer patients in general and 85% of patients in our test dataset for this drug corresponded to breast cancer. Here, ESR1 is linked to breast carcinoma.